No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | 1.73B | 5.64 | 58.02 | 43.5% | 9.32% | 1.89% | ||
| CORTCorcept Therapeutics Incorporated | 3.82B | 36.35 | 29.55 | 39.94% | 14.19% | 16.65% | 5.12% | 0.01 |
| GUTSFractyl Health, Inc. Common Stock | 308.28M | 2.01 | -1.24 | -22.5% | -40732.33% | -241.68% | 2.20 | |
| LXRXLexicon Pharmaceuticals, Inc. | 436.08M | 1.20 | -1.90 | 24.81% | -96.77% | -57.07% | 0.74 | |
| RZLTRezolute, Inc. | 229.96M | 2.48 | -2.53 | -52.45% | 0.01 | |||
| MISTMilestone Pharmaceuticals Inc. | 164.38M | 1.93 | -2.88 | -100% | -282.97% | 4.17 | ||
| ALTAltimmune, Inc. | 418.41M | 4.01 | -2.99 | -95.31% | -4195.75% | -45.21% | 0.01 | |
| BIOABioAge Labs, Inc. | 741.84M | 20.69 | -3.12 | -12.81% | -27.32% | 0.03 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 130.01M | 83.34M | 90.33M | 63.21M | 322.07M | 24M | 298K | 139K | 1.2M | 31.08M |
| Revenue Growth % | 4.69% | -0.36% | 0.08% | -0.3% | 4.1% | -0.93% | -0.99% | -0.53% | 7.66% | 24.81% |
| Cost of Goods Sold | 95.19M | 163.97M | 1.9M | 2.49M | 3.23M | 1.93M | 55.05M | 52.52M | 58.97M | 616K |
| COGS % of Revenue | 0.73% | 1.97% | 0.02% | 0.04% | 0.01% | 0.08% | 184.72% | 377.81% | 48.98% | 0.02% |
| Gross Profit | 34.83M | -80.64M | 88.44M | 60.72M | 318.84M | 22.07M | -54.75M | -52.38M | -57.77M | 30.46M |
| Gross Margin % | 0.27% | -0.97% | 0.98% | 0.96% | 0.99% | 0.92% | -183.72% | -376.81% | -47.98% | 0.98% |
| Gross Profit Growth % | 1.52% | -3.32% | 2.1% | -0.31% | 4.25% | -0.93% | -3.48% | 0.04% | -0.1% | 1.53% |
| Operating Expenses | 119.02M | 221.19M | 223.02M | 164M | 177.4M | 69.87M | 32.34M | 48.38M | 113.98M | 227.58M |
| OpEx % of Revenue | 0.92% | 2.65% | 2.47% | 2.59% | 0.55% | 2.91% | 108.53% | 348.08% | 94.67% | 7.32% |
| Selling, General & Admin | 23.84M | 43.04M | 66.2M | 63.75M | 56.84M | 47.23M | 0 | 0 | 0 | 131.9M |
| SG&A % of Revenue | 0.18% | 0.52% | 0.73% | 1.01% | 0.18% | 1.97% | - | - | - | 4.24% |
| Research & Development | 95.19M | 178.15M | 156.81M | 100.24M | 91.92M | 153.62M | 55.05M | 52.82M | 58.89M | 84.48M |
| R&D % of Revenue | 0.73% | 2.14% | 1.74% | 1.59% | 0.29% | 6.4% | 184.72% | 379.97% | 48.91% | 2.72% |
| Other Operating Expenses | 572K | 2.29M | 1.95M | 0 | 28.64M | -130.99M | -22.7M | -4.43M | 55.09M | 11.2M |
| Operating Income | 1.47M | -137.16M | -136.68M | -103.28M | 141.44M | -47.8M | -87.09M | -100.76M | -171.75M | -197.12M |
| Operating Margin % | 0.01% | -1.65% | -1.51% | -1.63% | 0.44% | -1.99% | -292.25% | -724.89% | -142.65% | -6.34% |
| Operating Income Growth % | 1.01% | -94.43% | 0% | 0.24% | 2.37% | -1.34% | -0.82% | -0.16% | -0.7% | -0.15% |
| EBITDA | 2.19M | -135.1M | -133.28M | -99.6M | 145.1M | -44.87M | -86.8M | -100.33M | -171.2M | -196.58M |
| EBITDA Margin % | 0.02% | -1.62% | -1.48% | -1.58% | 0.45% | -1.87% | -291.27% | -721.82% | -142.19% | -6.32% |
| EBITDA Growth % | 1.02% | -62.55% | 0.01% | 0.25% | 2.46% | -1.31% | -0.93% | -0.16% | -0.71% | -0.15% |
| D&A (Non-Cash Add-back) | 727K | 2.06M | 3.4M | 3.68M | 3.65M | 2.93M | 292K | 427K | 554K | 534K |
| EBIT | 10.99M | -124.88M | -128.67M | -99.77M | 144.79M | -44.03M | -87.09M | -100.46M | -170.31M | -184.82M |
| Net Interest Income | -6.15M | -4.27M | -5.03M | -17.27M | -17.33M | -11.78M | -668K | -1.18M | -5.37M | -3.29M |
| Interest Income | 572K | 2.29M | 1.95M | 3.51M | 3.35M | 2.77M | 134K | 1.6M | 7.73M | 12.29M |
| Interest Expense | 6.72M | 6.57M | 6.98M | 20.78M | 20.68M | 14.54M | 802K | 2.78M | 13.1M | 15.58M |
| Other Income/Expense | -6.15M | -4.27M | -5.03M | -17.27M | -17.33M | -10.77M | -668K | -1.18M | -5.37M | -3.29M |
| Pretax Income | -4.68M | -141.43M | -141.71M | -120.55M | 124.12M | -58.57M | -87.76M | -101.94M | -177.12M | -200.4M |
| Pretax Margin % | -0.04% | -1.7% | -1.57% | -1.91% | 0.39% | -2.44% | -294.49% | -733.41% | -147.11% | -6.45% |
| Income Tax | 0 | 4.51M | -12.66M | 0 | -6.01M | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 0.91% | 1% | 1.05% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -4.68M | -141.43M | -129.05M | -120.55M | 130.13M | -58.57M | -87.76M | -101.94M | -177.12M | -200.4M |
| Net Margin % | -0.04% | -1.7% | -1.43% | -1.91% | 0.4% | -2.44% | -294.49% | -733.41% | -147.11% | -6.45% |
| Net Income Growth % | 0.95% | -29.21% | 0.09% | 0.07% | 2.08% | -1.45% | -0.5% | -0.16% | -0.74% | -0.13% |
| Net Income (Continuing) | -4.68M | -141.43M | -122.99M | -120.55M | 130.13M | -58.57M | -87.76M | -101.94M | -177.12M | -200.4M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.05 | -1.36 | -1.23 | -1.14 | 1.11 | -0.63 | -0.61 | -0.62 | -0.80 | -0.63 |
| EPS Growth % | 0.97% | -29.09% | 0.1% | 0.07% | 1.97% | -1.57% | 0.03% | -0.02% | -0.29% | 0.21% |
| EPS (Basic) | -0.05 | -1.36 | -1.23 | -1.14 | 1.23 | -0.63 | -0.61 | -0.62 | -0.80 | -0.63 |
| Diluted Shares Outstanding | 103.59M | 103.86M | 105.24M | 105.83M | 116.75M | 110.84M | 145.65M | 165.73M | 221.13M | 320.03M |
| Basic Shares Outstanding | 103.59M | 103.86M | 105.12M | 105.74M | 106.22M | 110.84M | 145.65M | 165.73M | 221.13M | 320.03M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 532.4M | 357.87M | 322M | 173.32M | 337.75M | 157.72M | 88.92M | 140.87M | 176.55M | 246.19M |
| Cash & Short-Term Investments | 521.35M | 346.5M | 310.79M | 160.05M | 271.66M | 152.28M | 86.74M | 138.36M | 170.03M | 237.96M |
| Cash Only | 521.35M | 346.5M | 310.79M | 160.05M | 36.11M | 126.26M | 64.06M | 46.34M | 22.46M | 66.66M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 235.55M | 26.01M | 22.68M | 92.01M | 147.56M | 171.3M |
| Accounts Receivable | 911K | 7.49M | 4.83M | 5.92M | 56.53M | 395K | 14K | 28K | 1.01M | 3.47M |
| Days Sales Outstanding | 2.56 | 32.81 | 19.5 | 34.21 | 64.07 | 6.01 | 17.15 | 73.53 | 306.19 | 40.79 |
| Inventory | 0 | 0 | 1.95M | 4.68M | 4.24M | 0 | 0 | 0 | 381K | 231K |
| Days Inventory Outstanding | - | - | 374.42 | 685.75 | 479.32 | - | - | - | 2.36 | 136.88 |
| Other Current Assets | 10.14M | 3.88M | 4.43M | 2.67M | 0 | 0 | 0 | 2.48M | 5.13M | 4.53M |
| Total Non-Current Assets | 122.43M | 117.75M | 114.54M | 110.81M | 79.96M | 46.07M | 47.99M | 53.43M | 52.88M | 52.23M |
| Property, Plant & Equipment | 21.23M | 19.39M | 17.69M | 15.87M | 14.05M | 295K | 3.44M | 8.48M | 7.51M | 7.32M |
| Fixed Asset Turnover | 6.12x | 4.30x | 5.11x | 3.98x | 22.93x | 81.34x | 0.09x | 0.02x | 0.16x | 4.25x |
| Goodwill | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M |
| Intangible Assets | 53.36M | 53.36M | 51.88M | 50.12M | 19.72M | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | -413.61M | -468.39M | -4.88M | -4.51M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3.31M | 461K | 429K | 285K | 1.66M | 1.23M | 0 | 412K | 828K | 368K |
| Total Assets | 654.83M | 475.63M | 436.54M | 284.14M | 417.71M | 203.79M | 136.91M | 194.3M | 229.43M | 298.42M |
| Asset Turnover | 0.20x | 0.18x | 0.21x | 0.22x | 0.77x | 0.12x | 0.00x | 0.00x | 0.01x | 0.10x |
| Asset Growth % | 0.39% | -0.27% | -0.08% | -0.35% | 0.47% | -0.51% | -0.33% | 0.42% | 0.18% | 0.3% |
| Total Current Liabilities | 123M | 164.64M | 124.13M | 36.75M | 65.34M | 46.81M | 22.12M | 23.17M | 31.55M | 45.25M |
| Accounts Payable | 19.73M | 52.88M | 38.76M | 12.05M | 12.18M | 5.47M | 9.15M | 10.39M | 14.39M | 14.8M |
| Days Payables Outstanding | 75.64 | 117.7 | 7.45K | 1.77K | 1.38K | 1.03K | 60.69 | 72.25 | 89.06 | 8.77K |
| Short-Term Debt | 1.98M | 16.28M | 14.09M | 1.11M | 11.01M | 11.65M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 252K | -1.06M | 9.64M | 6.2M | 5.71M | 3.66M | 9.59M | 14.71M |
| Current Ratio | 4.33x | 2.17x | 2.59x | 4.72x | 5.17x | 3.37x | 4.02x | 6.08x | 5.60x | 5.44x |
| Quick Ratio | 4.33x | 2.17x | 2.58x | 4.59x | 5.10x | 3.37x | 4.02x | 6.08x | 5.58x | 5.44x |
| Cash Conversion Cycle | - | - | -7.06K | -1.05K | -832.34 | - | - | - | 219.49 | -8.59K |
| Total Non-Current Liabilities | 245.99M | 153.58M | 260.31M | 273.79M | 235.27M | 611K | 1.19M | 54M | 104.77M | 107.22M |
| Long-Term Debt | 100.96M | 85.17M | 231.58M | 243.89M | 234.17M | 0 | 0 | 48.58M | 99.51M | 100.3M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 1.1M | 611K | 1.19M | 5.42M | 5.26M | 6.92M |
| Deferred Tax Liabilities | 18.68M | 18.68M | 6.01M | 6.01M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 14.37M | 805K | 292K | 238K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 368.98M | 318.22M | 384.44M | 310.54M | 300.61M | 47.42M | 23.31M | 77.17M | 136.32M | 152.47M |
| Total Debt | 105.81M | 101.45M | 245.67M | 245M | 246.84M | 12.81M | 2.28M | 55.29M | 106.06M | 108.4M |
| Net Debt | -415.54M | -245.06M | -65.12M | 84.95M | 210.73M | -113.45M | -61.79M | 8.95M | 83.6M | 41.74M |
| Debt / Equity | 0.37x | 0.64x | 4.72x | - | 2.11x | 0.08x | 0.02x | 0.47x | 1.14x | 0.74x |
| Debt / EBITDA | 48.20x | - | - | - | 1.70x | - | - | - | - | - |
| Net Debt / EBITDA | -189.31x | - | - | - | 1.45x | - | - | - | - | - |
| Interest Coverage | 0.22x | -20.89x | -19.57x | -4.97x | 6.84x | -3.29x | -108.59x | -36.24x | -13.11x | -12.65x |
| Total Equity | 285.85M | 157.4M | 52.1M | -1.47B | 117.1M | 156.37M | 113.59M | 117.12M | 93.11M | 145.95M |
| Equity Growth % | 0.01% | -0.45% | -0.67% | -29.24% | 1.08% | 0.34% | -0.27% | 0.03% | -0.21% | 0.57% |
| Book Value per Share | 2.76 | 1.52 | 0.50 | -13.91 | 1.00 | 1.41 | 0.78 | 0.71 | 0.42 | 0.46 |
| Total Shareholders' Equity | 285.85M | 157.4M | 52.1M | -1.47B | 117.1M | 156.37M | 113.59M | 117.12M | 93.11M | 145.95M |
| Common Stock | 104K | 105K | 106K | 106K | 106K | 142K | 150K | 189K | 245K | 363K |
| Retained Earnings | -1.11B | -1.25B | -1.38B | -1.47B | -1.34B | -1.4B | -1.49B | -1.59B | -1.77B | -1.97B |
| Treasury Stock | -2.75M | -3.37M | -1.9M | -2.88M | -3.82M | -4.84M | -7.52M | -2.06M | -2.88M | -4.62M |
| Accumulated OCI | -219K | -195K | -222K | -12K | 84K | -6K | -10K | -428K | 31K | 119K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 184.78M | -175.63M | -185.39M | -148.61M | 113.81M | -142.97M | -87.02M | -88.85M | -161.9M | -178.78M |
| Operating CF Margin % | 1.42% | -2.11% | -2.05% | -2.35% | 0.35% | -5.96% | -292% | -639.22% | -134.47% | -5.75% |
| Operating CF Growth % | 3.44% | -1.95% | -0.06% | 0.2% | 1.77% | -2.26% | 0.39% | -0.02% | -0.82% | -0.1% |
| Net Income | -4.68M | -141.43M | -129.05M | -120.55M | 130.13M | -58.57M | -87.76M | -101.94M | -177.12M | -200.4M |
| Depreciation & Amortization | 727K | 2.06M | 3.4M | 3.68M | 3.65M | 2.93M | 292K | 427K | 554K | 534K |
| Stock-Based Compensation | 6.84M | 7.45M | 9.47M | 11.7M | 14.22M | 13.27M | 10.58M | 11.52M | 14.34M | 13.5M |
| Deferred Taxes | 3.55M | 16K | -12.66M | 0 | -6.01M | -110K | 49K | 0 | 0 | 0 |
| Other Non-Cash Items | 6.45M | -176K | 2.7M | 1.34M | 30.1M | -131.57M | 54K | 744K | -2.33M | -6.65M |
| Working Capital Changes | 171.89M | -43.55M | -59.26M | -44.77M | -58.29M | 31.08M | -10.23M | 402K | 2.66M | 14.24M |
| Change in Receivables | 124K | -4.08M | 166K | -1.1M | -50.61M | 53.23M | 381K | -14K | -982K | -2.46M |
| Change in Inventory | -5.79M | 6.23M | -1.95M | -2.73M | 437K | 345K | 0 | 0 | -381K | 150K |
| Change in Payables | 6.2M | 27.65M | -7.17M | -18.86M | 20.1M | -20.97M | -14.16M | 76K | 6.45M | 14.8M |
| Cash from Investing | -117.02M | 18.25M | 50.52M | 169.58M | -155.85M | 380.76M | 2.11M | -71.08M | -49.94M | -15.38M |
| Capital Expenditures | -910K | -231K | -228K | -95K | -70K | -87K | -1.22M | -1.33M | -470K | -1.03M |
| CapEx % of Revenue | 0.01% | 0% | 0% | 0% | 0% | 0% | 4.1% | 9.54% | 0.39% | 0.03% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 335K | 18.48M | 50.75M | 169.67M | -155.78M | 160.38M | 3.33M | -69.75M | 0 | 9.3M |
| Cash from Financing | -2.03M | 987K | 149.93M | -2.24M | -2.23M | -147.64M | 22.71M | 142.21M | 187.96M | 238.35M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 70K | 0 | 0 | 0 | 0 | 69.97M | 0 | 94.2M | 0 | -1.24M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 183.87M | -175.86M | -185.62M | -148.7M | 113.74M | -143.06M | -88.24M | -90.18M | -162.37M | -179.81M |
| FCF Margin % | 1.41% | -2.11% | -2.05% | -2.35% | 0.35% | -5.96% | -296.1% | -648.76% | -134.86% | -5.79% |
| FCF Growth % | 3.43% | -1.96% | -0.06% | 0.2% | 1.76% | -2.26% | 0.38% | -0.02% | -0.8% | -0.11% |
| FCF per Share | 1.77 | -1.69 | -1.76 | -1.41 | 0.97 | -1.29 | -0.61 | -0.54 | -0.73 | -0.56 |
| FCF Conversion (FCF/Net Income) | -39.47x | 1.24x | 1.44x | 1.23x | 0.87x | 2.44x | 0.99x | 0.87x | 0.91x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -1.64% | -63.81% | -123.2% | - | 111.13% | -42.84% | -65.01% | -88.37% | -168.5% | -167.66% |
| Return on Invested Capital (ROIC) | - | - | - | - | 32.36% | -19.34% | -137.91% | -84.97% | -85.09% | -81.14% |
| Gross Margin | 26.79% | -96.76% | 97.9% | 96.06% | 99% | 91.96% | -18371.81% | -37681.29% | -4798.01% | 98.02% |
| Net Margin | -3.6% | -169.71% | -142.86% | -190.71% | 40.4% | -244.11% | -29448.99% | -73341.01% | -14710.88% | -644.78% |
| Debt / Equity | 0.37x | 0.64x | 4.72x | - | 2.11x | 0.08x | 0.02x | 0.47x | 1.14x | 0.74x |
| Interest Coverage | 0.22x | -20.89x | -19.57x | -4.97x | 6.84x | -3.29x | -108.59x | -36.24x | -13.11x | -12.65x |
| FCF Conversion | -39.47x | 1.24x | 1.44x | 1.23x | 0.87x | 2.44x | 0.99x | 0.87x | 0.91x | 0.89x |
| Revenue Growth | 468.89% | -35.9% | 8.4% | -30.03% | 409.54% | -92.55% | -98.76% | -53.36% | 766.19% | 2481.48% |
| 2024 | |
|---|---|
| Reportable | 31.08M |
| Reportable Growth | - |
Lexicon Pharmaceuticals, Inc. (LXRX) reported $70.9M in revenue for fiscal year 2024. This represents a 3733% increase from $1.8M in 2011.
Lexicon Pharmaceuticals, Inc. (LXRX) grew revenue by 2481.5% over the past year. This is strong growth.
Lexicon Pharmaceuticals, Inc. (LXRX) reported a net loss of $68.6M for fiscal year 2024.
Lexicon Pharmaceuticals, Inc. (LXRX) has a return on equity (ROE) of -167.7%. Negative ROE indicates the company is unprofitable.
Lexicon Pharmaceuticals, Inc. (LXRX) had negative free cash flow of $48.8M in fiscal year 2024, likely due to heavy capital investments.